Researchers have found that the characteristics of tumors are determined by their genetic makeup. Therefore, cancer treatment can begin at the genetic level by targeting specific genes to influence tumor behavior and achieve therapeutic outcomes. Tumor driver genes are associated with cancer progression and can help assess prognosis, as well as the risks of recurrence and metastasis. Drug-related genes provide valuable guidance for therapy selection by indicating drug sensitivity or resistance. Understanding the genetic profile of a tumor forms the basis for treatment planning. By identifying the appropriate genes, more precise and effective cancer therapies can be delivered, maximizing clinical benefit.

Genecast ctDNA Comprehensive Kit is a next-generation sequencing (NGS)-based genomic profiling assay utilizing liquid biopsy technology. It is designed to detect plasma sample from patient with solid tumors, performing comprehensive sequencing and analysis of 769 cancer-related genes.

The assay identifies multiple types of genomic alterations, including single nucleotide variants (SNVs), insertions/deletions (Indels), copy number variations (CNVs), and gene fusions. It also evaluates key genomic signatures such as microsatellite instability (MSI) status and tumor mutational burden (TMB). The results provide reference information to support therapeutic decision-making for both targeted therapy and immunotherapy.

Applicable Cancer Types

Specifications